

RESEARCH

Open Access

Peritoneal carcinomatosis from ovarian cancer: chemosensitivity test and tissue markers as predictors of response to chemotherapy

Chiara Arienti¹, Anna Tesei¹, Giorgio Maria Verdecchia², Massimo Framarini², Salvatore Virzi³, Antonio Grassi³, Emanuela Scarpì¹, Livia Turci¹, Rosella Silvestrini¹, Dino Amadori¹ and Wainer Zoli^{1*}

Abstract

Background: Platinum-based regimens are the treatments of choice in ovarian cancer, which remains the leading cause of death from gynecological malignancies in the Western world. The aim of the present study was to compare the advantages and limits of a conventional chemosensitivity test with those of new biomolecular markers in predicting response to platinum regimens in a series of patients with peritoneal carcinomatosis from ovarian cancer.

Methods: Fresh surgical biopsy specimens were obtained from 30 patients with primary or recurrent peritoneal carcinomatosis from ovarian cancer. *ERCC1*, *GSTP1*, *MGMT*, *XPD*, and *BRCA1* gene expression levels were determined by Real-Time RT-PCR. An *in vitro* chemosensitivity test was used to define a sensitivity or resistance profile to the drugs used to treat each patient.

Results: *MGMT* and *XPD* expression was directly and significantly related to resistance to platinum-containing treatment ($p = 0.036$ and $p = 0.043$, respectively). Significant predictivity in terms of sensitivity and resistance was observed for *MGMT* expression (75.0% and 72.5%, respectively; $p = 0.03$), while high predictivity of resistance (90.9%) but very low predictivity of sensitivity (37.5%) ($p = 0.06$) were observed for *XPD*. The best overall and significant predictivity was observed for chemosensitivity test results (85.7% sensitivity and 91.3% resistance; $p = 0.0003$).

Conclusions: The *in vitro* assay showed a consistency with results observed *in vivo* in 27 out of the 30 patients analyzed. Sensitivity and resistance profiles of different drugs used *in vivo* would therefore seem to be better defined by the *in vitro* chemosensitivity test than by expression levels of markers.

Background

The selection of a chemotherapy regimen for individual tumors is normally based on histology, clinical characteristics of the patient and retrospective evidence from randomized clinical trials. However, patients with the same tumor histotype, especially in solid malignancies, often respond differently to the same chemotherapy regimen due to intertumor heterogeneity. Despite knowledge of such heterogeneity, chemotherapy is still largely empirically planned, and the acquisition of

information for tailored therapy has consequently become a priority in the management of cancer patients today.

Such a goal was intensively pursued in the 1980s by American and European research groups who developed a number of chemosensitivity tests using fresh material from human tumors and based on the determination of cell proliferation (clonogenic potential and 3H-thymidine incorporation) or total cell evaluation (dye exclusion, sulphorhodamine blue, MTT assay and ATP bioluminescence) [1-6]. The results obtained from the different tests were compared and their clinical relevance verified in a number of translational clinical studies [5,7-10]. However, various methodological

* Correspondence: w.zoli@irst.emr.it

¹Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, Italy

Full list of author information is available at the end of the article

problems and technical skills required have limited the widespread clinical use of *in vitro* experimental results. With the advent of molecular biology at the end of the nineties, attention moved towards the search for molecular and genetic markers involved in proliferation and DNA repair processes that might be predictive of response to both conventional cytotoxic and target therapy drugs [11].

Platinum or platinum-based regimens are the treatment of choice in ovarian cancers, which remains the leading cause of death from gynecological malignancies in the Western world [12]. The absence of specific symptoms in the early stages of the disease results in the majority of patients being diagnosed when the disease is advanced [13]. Currently, standard primary therapy for advanced disease involves surgical debulking followed by platinum/taxane-based chemotherapy [14]. However, despite initially high response rates, a large proportion of patients often experience peritoneal relapse. Recurrent disease is treated with the same regimen used for first-line chemotherapy (i.e., re-induction therapy) or with second- or third-line regimens.

Resistance to platinum alone or in combination is multifactorial. Several studies have attempted to clarify the mechanisms behind resistance to platinum-based chemotherapy, whether intrinsic, as observed in colorectal, prostate, breast or lung cancer, or acquired during treatment. At present, numerous molecular pathways are known to be involved in drug resistance, especially that of platinum compounds. Among such pathways, increased DNA repair and enhanced drug efflux and/or inactivation play an important role in platinum resistance and may also be instrumental in predicting patient prognosis in a clinical setting [11,15,16].

One of the mechanisms involved in DNA repair is the nucleotide excision repair (NER) system, which recognizes helix-distorting base lesions and is presumed to be one of the determinants of platinum resistance [15]. The role of excision repair cross-complementation group 1 (*ERCC1*) in the NER pathway is to incise the DNA strand on the 5' site relative to platinated DNA damage, and its overexpression has been associated with clinical resistance to cisplatin [17,18]. Xeroderma pigmentosum group D (*XPD*) is another of the several genes involved in the NER pathway. In particular, *XPD* opens an approximately 30-baseline DNA segment around the damage. It has also been reported that underexpression of *XPD* in cells with transcription coupled-NER-deficiency results in hypersensitivity to cisplatin [19].

DNA adducts at the O6-position of guanine can be repaired by NER but also by O6 methylguanine-DNA methyltransferase (*MGMT*), which is described as a competitor of the NER mechanisms of repair [20]. Preliminary studies have shown that *MGMT*-deficient cells

are unable to repair damage and are more sensitive to the effect induced by alkylating agents than *MGMT*-proficient cells [21].

Breast cancer gene 1 (*BRCA1*), an essential component of multiple DNA damage repair pathways, is considered to be a differential modulator of survival for cells treated with cisplatin. Preclinical and clinical studies have reported that high levels of *BRCA1* are associated with cisplatin chemoresistance [18,22,23].

Acquired resistance to DNA adduct formation induced by platinum compounds may be also a consequence of a reduction in drug accumulation in cells due to drug inactivation and/or enhanced efflux. The glutathione *S*-transferase (*GST*) makes cisplatin more anionic and more readily exported from cells by the ATP-dependent glutathione *S*-conjugate export (*GS-X*) pump (*MRP1* or *MRP2*). Some, but not all, translational studies have suggest that the glutathione metabolic pathway may have a role in acquired drug resistance to platinum drugs [15,24,25].

The aims of the present study were to compare the advantages and limits of a conventional chemosensitivity *in vitro* test with those of potentially interesting biomolecular markers in predicting response to platinum or platinum based regimens, in a series of patients with peritoneal carcinomatosis from ovarian cancer.

Patients and Methods

Patients

Thirty-two patients with peritoneal carcinomatosis from primary advanced (7 cases) or recurrent (25 cases) ovarian cancer were recruited for the *in vitro* chemosensitivity assay and for analysis of biomarkers potentially predictive of resistance to platinum compounds. Patients underwent surgical resection at Pierantoni Hospital in Forlì and or at Bentivoglio Hospital in Bologna. Inclusion criteria were histological confirmation of advanced or recurrent ovarian cancer and pre- or a postsurgery chemotherapy based on a platinum compound (carboplatin/taxol or cisplatin/adriamycin or carboplatin/gemcitabine or carboplatin as monochemotherapy). It was not possible to perform the *in vitro* chemosensitivity test in 2 patients due to insufficient material. The remaining 30 patients all had serous tumor subtypes. Median age of patients was 60 ± 13.3 years (range 32-81).

Informed consent was obtained before surgical treatment and patients were required to be accessible for follow-up. The study protocol was approved by the Local Ethics Committee. In order to evaluate the correlation between gene expression or *in vitro* chemosensitivity and clinical response to platinum-containing treatment, patients were subdivided into responders (partial or complete clinical response and stable disease) or non-responders (progressive disease).

Treatment Evaluation

Clinical response was evaluated by measuring circulating CA125 levels before each treatment cycle. Tumor imaging was performed every three cycles using ultrasonography or CT/MRI scans. The same clinical and instrumental evaluation was carried out every 3 months after the end of treatment.

Sample Collection

Immediately after surgical resection, tumor specimens were sampled and analyzed (under sterile conditions) by a pathologist to confirm the tumor representativity of the samples. A part of the tissue was then stored in RNAlater[®] Tissue Collection (Invitrogen, Carlsbad, CA) at a temperature of +4°C to preserve mRNA integrity, while another part was used immediately for the chemosensitivity test.

Real-Time RT-PCR Analysis

Total RNA was extracted from fresh surgical biopsies using TRIzol[®] Reagent within 2 or 3 hours of surgery, in accordance with the manufacturer's instructions (Invitrogen). Reverse transcription (RT) reactions were performed in a 20- μ l volume containing 800 ng of total RNA using iScript TM cDNA Synthesis kit (Bio-Rad Laboratories, Hercules, CA) and analyzed by Real Time RT-PCR (MyiQ System, Bio-Rad) to detect the expression of the genes *MGMT*, *BRCA1*, *ERCC1*, *GSTP1*, and *XPD*. Primers for mRNA amplification were designed using Beacon Designer Software (version 4, BioRad) and sequences are listed in Table 1. The standard reaction volume was 25 μ l containing 2 μ l of cDNA template, 1 \times SYBR Green Mix and 5 μ M of forward and reverse primers. The mixture was subjected to the following cycling conditions: 95°C for 1 min and 30 s, followed by 40 cycles of amplification for 15 s at 95°C and 30 s at 59°C (for *XPD*) or 60°C (for *MGMT*, *BRCA1*, *ERCC1*, *GSTP1*, β_2 -microglobulin, and hypoxanthine phosphoribosyltransferase (*HPRT*)). The amount of mRNA of each marker was normalized to the endogenous references β_2 -microglobulin and *HPRT* using Gene Expression Macro Software (Version 1.1) (BioRad).

Commercial RNA control derived from a pool of normal ovarian tissue mRNA was used as calibrator.

The efficiency of amplification, which never exceeded 5% variability in the different experiments, was used to determine the relative expression of mRNA and was calculated using Gene Expression Macro Software (Version 1.1) (BioRad). The reproducibility of Real-Time PCR results was verified in triplicate, and the coefficient of variation (CV), calculated from the three C_t values, was always < 1.5%.

In vitro Chemosensitivity Test

A cell suspension was obtained after 4-16 hours of enzymatic digestion of fresh tumor tissue. Cells were counted and plated at a density of 1,000,000 cells/well in 96-well flat-bottomed microtiter plates (100 μ l of cell suspension/well). Experiments were run in octuplicate. The optical density of treated and untreated cells was determined at a wavelength of 540 nm using a fluorescence plate reader.

Cells were exposed for 72 hours to 1, 10 and 100 μ M of cisplatin or adriamycin; 8, 80 and 800 μ M of carboplatin; 4, 40 and 400 μ M of gemcitabine; and 0.6, 6 and 60 μ M of taxol. Drugs were used at concentrations corresponding to peak plasma levels and were also tested at doses equivalent to one-tenth of and tenfold the peak plasma value. Drug activity was assessed by sulforhodamine B assay according to the method of Skehan et al [4]. PC3 tumor cell line, for which the dose-response curve to the anticancer agents used is known, was used as an internal control in all single experiments performed.

Statistical Analysis

The relationship between continuous (gene expression) and dichotomous variables was analyzed using a non-parametric ranking statistic (median test) [26]. Spearman's correlation coefficient (r_s) was used to investigate the correlation between the mRNA expression of different genes, such as *MGMT*, *BRCA1*, *ERCC1*, *GSTP1* and *XPD*, considered as continuous variables. Receiver operating characteristic (ROC) analysis was performed

Table 1 Oligonucleotides used for Real-Time PCR

Gene name	5' to 3' forward primer	5' to 3' reverse primer	Annealing temperature
<i>MGMT</i>	tcttcacatcccgtttcc	attgccttcattgctcctc	60°C
<i>BRCA1</i>	gctcgctgagacttctctg	gataaatccatttctttctgtcc	60°C
<i>ERCC1</i>	tcagtcaacaaaacggacagtcag	tccttgggtctttcccagagc	60°C
<i>GSTP1</i>	aacatgaggcgggcaag	gttgtagtcagcgaaggag	60°C
<i>XPD</i>	aagcaggaggcgagaag	cctcatagaatcggcagtg	59°C
<i>HPRT</i>	agacttgcttctctgtcagg	gtctggcttatccaacattcg	60°C
<i>Beta2-microglobulin</i>	cgctactctctttctg	agacacatgaattcaggaa	60°C

for both individual markers and their combinations. We considered an algorithm that renders a single composite score using the linear predictor fitted from a binary regression model. This algorithm has been justified to be optimal under the linearity assumption [27,28] that the ROC curve is maximized (i.e., best sensitivity) at every threshold value. The chi-square test was used to compare dichotomous variables.

All statistical analyses were performed with SAS Statistical Software (version 9.1, SAS Institute Inc., Cary, NC). Two-sided p values < 0.05 were considered significant.

Results

The analysis of the comparison between *in vitro* and clinical results was performed on 30 cases with serous tumors. Fifteen patients obtained complete cytoreduction, 6 had minimal residual disease, 4 had maximum residual disease, and the remaining 5 had unresectable disease. The majority of patients (56%) underwent carboplatin/taxol chemotherapy, 20% received cisplatin/adriamycin, 10% carboplatin as monochemotherapy, and 6% carboplatin/gemcitabine or carboplatin/taxol/gemcitabine (Table 2).

Gene Expression Analysis

Of the 5 genes analyzed, *MGMT* and *XPD* expression was directly and significantly related to resistance to cisplatin-including regimens (p = 0.03 and p = 0.04, respectively) (Table 3). In particular, median expression

Table 2 Tumor and patient characteristics and treatment information of the case series

Characteristics	No. patients
Cancer	
Primary	7
Recurrent	23
Histological type	
Serous	30
Results of cytoreduction	
CC0	15
CC1	6
CC2	4
Unresectable	5
Peritoneal Cancer Index (mean and range)	22.7 (6-39)
Type of treatment	
Carboplatin/taxol	17
Cisplatin/adriamycin	6
Carboplatin	3
Carboplatin/gemcitabine	2
Carboplatin/taxol/gemcitabine	2

CC0, complete cytoreduction; CC1, minimal residual disease; CC2, maximum residual disease

Table 3 Tumor gene expression to platinum-containing treatment in responders and non-responders

Gene	Median expression values (range)			p
	Total patients	Responders	Non-responders	
<i>MGMT</i>	0.90 (0-20.0)	0.57 (0-2.2)	2.0 (0-20.0)	0.03
<i>XPD</i>	0.80 (0.027-12.4)	0.52 (0.027-2.0)	1.9 (0.11-12.4)	0.04
<i>BRCA1</i>	2.60 (0-87.4)	1.73 (0.20-6.47)	3.0 (0-87.4)	0.59
<i>ERCC1</i>	1.50 (0.47-15.0)	2.30 (0.7-7.02)	1.4 (0.47-15.0)	0.93
<i>GSTP1</i>	1.75 (0.15-45.0)	1.47 (0.15-7.5)	1.7 (0.71-45.0)	0.65

values of *MGMT* and *XPD* in tumors were about four-fold higher in non-responders than in responders.

All 5 genes were generally poorly correlated with each other; with correlation coefficients (r_s) ranging from 0.577 to 0.074. In particular, of the two genes whose expression was maximally predictive of sensitivity or resistance to clinical treatment, *XPD* was not significantly related to *ERCC1* or *GSTP1*, and showed borderline clinical significance with *MGMT*. The second, *MGMT*, was significantly related, albeit with a very poor correlation coefficient, to the other four genes (Table 4). The accuracy in predicting sensitivity or resistance to clinical treatment was analyzed for each single gene and for combinations of genes not significantly correlated with each other. Results were expressed as the area under the curve (AUC) and in terms of sensitivity, specificity and overall accuracy (Table 5). AUC values were maximum for *MGMT* (0.73; 95% CI 0.53-0.94) and *XPD* (0.70; 95% CI 0.48-0.91), and different gene combinations did not provide more accurate information. Only the 5 markers considered together slightly improved the AUC value (0.79; CI 0.62-0.97).

These results were paralleled by those expressed as overall accuracy: 78.5% and 75% for *MGMT* and *XPD*, respectively and 75% for the 5 markers considered together. *XPD* expression was characterized by the highest sensitivity (89.4%) but very low specificity (44.4%), while *MGMT* showed both high sensitivity (78.9%) and specificity (77.8%).

In Vitro Chemosensitivity Test

In parallel, a molecular profile of chemosensitivity to all the drugs used in the clinical treatment was generated for each tumor. Patients were subdivided into responders

Table 4 Correlation between XPD or MGMT and other marker expression

	<i>XPD</i>		<i>BRCA1</i>		<i>ERCC1</i>		<i>GSTP1</i>	
	r_s	p	r_s	p	r_s	p	r_s	p
<i>XPD</i>			0.476	0.007	0.074	0.696	0.307	0.099
<i>MGMT</i>	0.355	0.054	0.548	0.002	0.432	0.017	0.577	0.001

r_s , correlation coefficient

Table 5 Sensitivity and specificity of individual markers or their combination in predicting response to treatment

	AUC	Cut-off \geq	Sensitivity (%)	Specificity (%)	Overall accuracy (%)
MGMT	0.73	0.72	78.9	77.8	78.5
XPD	0.70	0.22	89.4	44.4	75.0
BRCA1	0.62	2.43	63.1	66.6	64.3
ERCC1	0.56	1.37	73.7	44.4	64.3
GSTP1	0.57	1.09	63.1	55.5	60.7
MGMT + XPD	0.67	-	63.1	55.5	60.7
XPD + ERCC1	0.69	-	73.9	44.4	67.8
XPD + GSTP1	0.69	-	78.9	44.4	67.8
Five markers together	0.79	-	74.0	77.8	75.0

AUC, area under the curve

(complete or partial clinical response and stable disease), or non-responders (progressive disease), to evaluate the correlation between *in vitro* chemosensitivity assay and clinical response to platinum-containing treatments (Table 6). Seventeen patients (56.6%) were treated with carboplatin and taxol, of whom 6 had primary advanced and 11 recurrent ovarian cancer. We did not observe any significant differences in either *in vitro* or clinical sensitivity or resistance between primary and recurrent cancers. Considering the 2 subgroups together, concordance between *in vitro* results and clinical response was observed in 14 cases (3 in terms of sensitivity, 11 in terms of resistance). The 3 cases in whom there was no correspondence between *in vitro* and *in vivo* results were all *in vitro* sensitive to one drug (carboplatin or taxol); two showed clinical progression and one stable disease (Table 6). Similarly, in the subgroup of 6 patients treated with cisplatin and adriamycin, 3 were *in vitro*-sensitive to both drugs and showed a clinical response, while 3 were *in vitro* resistant to both drugs and showed disease progression. Patients treated with carboplatin (3 cases: 1 primary and 2 recurrent), carboplatin and gemcitabine (2 cases), or carboplatin, taxol and gemcitabine (2 cases) were *in vitro* resistant to all the drugs and all had disease progression.

Comparison between the two *In Vitro* Approaches

Results of the clinical response predictivity of the most relevant markers, considered singly or in combination, and of the *in vitro* chemosensitivity test are shown in Table 7. Significant predictivity in terms of sensitivity and resistance to the different cisplatin-based regimens was observed for MGMT expression (75.0% and 72.5%, respectively; $p = 0.03$), while high predictivity with regard to resistance (90.9%), but very low predictivity in terms of sensitivity (37.5%) ($p = 0.06$) were observed for XPD. The combined analysis of the five markers gave the highest predictivity with regard to resistance but

Table 6 Correspondence between *in vitro* activity and clinical efficacy in individual tumors

	<i>In vitro</i> results	Clinical results	
Primary	Carboplatin/taxol		
	S/S	S	
	R/S	S	
	R/R	R	
	R/R	R	
	R/R	R	
	R/R	R	
	R/R	R	
	R	R	
		Carboplatin	
	R	R	
Recurrent	Carboplatin/taxol		
	S/S	S	
	R/S	R	
	S/S	S	
	S/R	R	
	R/R	R	
	R/R	R	
	R/R	R	
	R/R	R	
	R/R	R	
	R/R	R	
	R/R	R	
	R/R	R	
	R/R	R	
		Cisplatin/adriamycin	
	R/R	R	
	S/S	S	
S/S	S		
S/S	S		
R/R	R		
R/R	R		
	Carboplatin		
R	R		
R	R		
	Carboplatin/gemcitabine		
R/R	R		
R/R	R		
	Carboplatin/taxol/gemcitabine		
R/R/R	R		
R/R/R	R		

S, sensitive; R, resistant

Table 7 Predictivity of clinical response by different biomarkers or *in vitro* chemosensitivity test

	Sensitivity (%)	Resistance (%)	p
Markers			
MGMT	75.0	72.5	0.03
XPD	37.5	90.9	0.06
Five markers	33.3	100	0.07
Chemosensitivity test	85.7	91.3	0.0003

very low predictivity in relation to sensitivity (100% and 33.3%, respectively; $p = 0.07$).

The best overall and significant predictivity was observed for the *in vitro* chemosensitivity test results (85.7% sensitivity and 91.3% resistance, $p = 0.0003$). The markers were not effective in predicting resistance or sensitivity to treatment with platinum when recurrent (23) or primary (7) patients were analyzed. Conversely, the chemosensitivity test maintained a significant ability to predict response to chemotherapy in both series of patients.

Discussion

Prediction of response to drugs at preclinical level could help physicians to plan more effective tailored therapy for individuals, reduce undesirable drug toxicity and lower the cost of health care. In ovarian cancer, despite the heterogeneity of treatments available for peritoneal carcinomatosis, the majority of patients receive platinum-containing chemotherapy in either first- or second- and third-line settings. The use of the re-induction therapy in peritoneal carcinomatosis underlines the importance of studying these patients in terms of preclinical evaluation for response to platinum-containing treatments in order to avoid inactive treatments caused by acquired resistance.

There is a large body of literature highlighting a number of biomarkers as potential candidates for predicting resistance or sensitivity to treatment [11,17-22,29-33]. In the present study, we investigated the role of potentially interesting biomolecular markers and evaluated the relevance of a conventional *in vitro* chemosensitivity test for predicting clinical response to platinum-based regimens in patients with peritoneal carcinomatosis from ovarian cancer.

Among the markers studied, *MGMT* and *XPD* gene expression proved effective in predicting response to platinum-containing therapy. The *MGMT* gene showed good prediction with regard to both sensitivity and resistance, which, is in contrast to results obtained by Codegani and coworkers who failed to find any relation between *MGMT* expression, detected by northern blot analysis, and response to platinum-based therapy in patients with primary ovarian cancer [34]. *XPD* expression was strongly correlated with drug resistance but weakly associated with drug sensitivity. These results are in agreement with those of Aloyz and coworkers who observed a relationship between *XPD* overexpression and resistance to alkylating agents in human tumor cell lines [35].

In our study the highest predictivity was observed for the *in vitro* chemosensitivity test used to evaluate drug activity. A strong correlation between *in vitro* results

and clinical response was observed in 27 out of the 30 patients analyzed, with a predictivity of 85.7% in terms of sensitivity and of 91.3% in terms of resistance. The important predictive relevance of the *in vitro* chemosensitivity test confirms findings published by other authors on a large number of solid and hematologic tumors [9,36-40].

Evaluation of the two analytical approaches highlights the lower cost and higher accuracy, but also the longer execution time and larger amount of tumor material required by the chemosensitivity test compared to Real-Time PCR determination of biomarkers, which gives rapid results using only a few nanograms of RNA.

Conclusions

In conclusion, it no longer appears ethical to treat patients with drugs to which resistance can be predicted by preclinical experimental techniques in more than 90% of cases. One solution might therefore be to use tumor material from ovarian carcinomatosis as a model for *in vitro* phase II studies to explore the antitumor activity of conventional and novel drugs, singly or in combination.

List of abbreviations

NER: nucleotide excision repair; *ERCC1*: excision repair cross-complementation group1; *XPD*: xeroderma pigmentosum group D; *MGMT*: O6 methylguanine-DNA methyltransferase; *BRCA1*: breast cancer gene 1; *GST*: glutathione S-transferase; RT: reverse transcription; ROC: receiving operating characteristic; AUC: area under the curve.

Acknowledgements

The authors would like to thank Gráinne Tierney for editing the manuscript.

Author details

¹Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, Italy. ²Department of Surgery and Advanced Cancer Therapies, Morgagni-Pierantoni Hospital, Forlì, Italy. ³Department of Surgery, Bentivoglio Hospital, Bologna, Italy.

Authors' contributions

WZ, RS, AT and DA designed the study. CA was responsible for data acquisition and carried out the molecular genetic assays and *in vitro* analyses. LT performed the *in vitro* analyses. GMV, MF, SV and AG were responsible for patient recruitment and provided the surgical material. ES performed the statistical analyses. CA, WZ and RS drafted the manuscript. DA and RS reviewed the text for conceptual and analytic integrity. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 30 March 2011 Accepted: 20 June 2011

Published: 20 June 2011

References

1. Hamburger AW, Salmon SE: Primary bioassay of human tumor stem cells. *Science* 1977, **197**:461-463.
2. Kern DH, Drogemuller CR, Kennedy MC, Hildebrand-Zanki SU, Tanigawa N, Sondak VK: Development of a miniaturized, improved nucleic acid precursor incorporation assay for chemosensitivity testing of human solid tumors. *Cancer Res* 1985, **45**:5436-5441.

3. Weisenthal LM, Marsden JA, Dill PL, Macaluso CK: **A novel dye exclusion method for testing in vitro chemosensitivity of human tumors.** *Cancer Res* 1983, **43**:749-757.
4. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR: **New colorimetric cytotoxicity assay for anticancer-drug screening.** *J Natl Cancer Inst* 1990, **82**:1107-1112.
5. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB: **Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing.** *Cancer Res* 1987, **47**:936-942.
6. Kangas L, Gronroos M, Nieminen AL: **Bioluminescence of cellular ATP: a new method for evaluating cytotoxic agents in vitro.** *Med Biol* 1984, **62**:338-343.
7. Von Hoff DD, Clark GM, Stogdill BJ, Sarosdy MF, O'Brien MT, Casper JT, Mattox DE, Page CP, Cruz AB, Sandbach JF: **Prospective clinical trial of a human tumor cloning system.** *Cancer Res* 1983, **43**:1926-1931.
8. Sondak VK, Bertelsen CA, Tanigawa N, Hildebrand-Zanki SU, Morton DL, Korn EL, Kern DH: **Clinical correlations with chemosensitivities measured in a rapid thymidine incorporation assay.** *Cancer Res* 1984, **44**:1725-1728.
9. Bertelsen CA, Sondak VK, Mann BD, Korn EL, Kern DH: **Chemosensitivity testing of human solid tumors. A review of 1582 assays with 258 clinical correlations.** *Cancer* 1984, **53**:1240-1245.
10. Keepers YP, Pizao PE, Peters GJ, van Ark-Otte J, Winograd B, Pinedo HM: **Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing.** *Eur J Cancer* 1991, **27**:897-900.
11. Richardson A, Kaye SB: **Drug resistance in ovarian cancer: the emerging importance of gene transcription and spatio-temporal regulation of resistance.** *Drug Resist Updat* 2005, **8**:311-321.
12. Bonnefoi H, A'Hern RP, Fisher C, Macfarlane V, Barton D, Blake P, Shepherd JH, Gore ME: **Natural history of stage IV epithelial ovarian cancer.** *J Clin Oncol* 1999, **17**:767-775.
13. Funicelli L, Travaini LL, Landoni F, Trifiro' G, Bonello L, Bellomi M: **Peritoneal carcinomatosis from ovarian cancer: the role of CT and [18F]FDG-PET/CTL.** *Abdom Imaging* 2010, **35**:701-707.
14. Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, Wadler S, Sikel J: **Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group.** *J Clin Oncol* 2001, **19**:1001-1007.
15. Kelland L: **The resurgence of platinum-based cancer chemotherapy.** *Nat Rev Cancer* 2007, **7**:573-584.
16. Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, Danenberg KD, Groshen S, Tsao-Wei DD, Danenberg PV, Lenz HJ: **ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy.** *J Clin Oncol* 2001, **19**:4298-4304.
17. Rosell R, Taron M, Barnadas A, Scagliotti G, Sarries C, Roig B: **Nucleotide excision repair pathways involved in Cisplatin resistance in non-small-cell lung cancer.** *Cancer Control* 2003, **10**:297-305.
18. Weberpals J, Garbuio K, O'Brien A, Clark-Knowles K, Doucette S, Antoniouk O, Goss G, Dimitroulakos J: **The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer.** *Int J Cancer* 2009, **124**:806-815.
19. Furuta T, Ueda T, Aune G, Sarasin A, Kraemer KH, Pommier Y: **Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells.** *Cancer Res* 2002, **62**:4899-4902.
20. Kaina B, Christmann M, Naumann S, Roos WP: **MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents.** *DNA Repair (Amst)* 2007, **6**:1079-1099.
21. Yarosh DB, Foote RS, Mitra S, Day RS: **Repair of O6-methylguanine in DNA by demethylation is lacking in Mer- human tumor cell strains.** *Carcinogenesis* 1983, **4**:199-205.
22. Quinn JE, Carser JE, James CR, Kennedy RD, Harkin DP: **BRCA1 and implications for response to chemotherapy in ovarian cancer.** *Gynecol Oncol* 2009, **113**:134-142.
23. Tassone P, Di Martino MT, Ventura M, Pietragalla A, Cucinotto I, Calimeri T, Bulotta A, Neri P, Caraglia M, Tagliaferri P: **Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo.** *Cancer Biol Ther* 2009, **8**:648-653.
24. Lewis AD, Hayes JD, Wolf CR: **Glutathione and glutathione-dependent enzymes in ovarian adenocarcinoma cell lines derived from a patient before and after the onset of drug resistance: intrinsic differences and cell cycle effects.** *Carcinogenesis* 1988, **9**:1283-1287.
25. Yang P, Ebbert JO, Sun Z, Weinsilboum RM: **Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: a review.** *J Clin Oncol* 2006, **24**:1761-1769.
26. Siegel S: **Nonparametric statistics.** London: McGraw-Hill Ltd; 1956.
27. Eguchi S, Copas J: **A class of logistic-type discriminant functions.** *Biometrika* 2002, **89**:1-22.
28. McIntosh MW, Pepe MS: **Combining several screening tests: optimality of the risk score.** *Biometrics* 2002, **58**:657-664.
29. Naniwa J, Kigawa J, Kanamori Y, Itamochi H, Oishi T, Shimada M, Shimogai R, Kawaguchi W, Sato S, Terakawa N: **Genetic diagnosis for chemosensitivity with drug-resistance genes in epithelial ovarian cancer.** *Int J Gynecol Cancer* 2007, **17**:76-82.
30. O'Toole SA, Sheppard BL, Laios A, O'Leary JJ, McGuinness EP, D'Arcy T, Bonnar J: **Potential predictors of chemotherapy response in ovarian cancer—how do we define chemosensitivity?** *Gynecol Oncol* 2007, **104**:345-351.
31. Bignotti E, Tassi RA, Calza S, Ravaggi A, Romani C, Rossi E, Falchetti M, Odicino FE, Pecorelli S, Santin AD: **Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy.** *Gynecol Oncol* 2006, **103**:405-416.
32. Darcy KM, Birrer MJ: **Translational research in the Gynecologic Oncology Group: evaluation of ovarian cancer markers, profiles, and novel therapies.** *Gynecol Oncol* 2010, **117**:429-439.
33. Santini D, Caraglia M, Vincenzi B, Hohen I, Scarpa S, Budillon A, Tonini G: **Mechanisms of disease: preclinical reports of antineoplastic synergistic action of bisphosphonates.** *Nat Clin Pract Oncol* 2006, **3**:325-338.
34. Codegoni AM, Broggin M, Pitelli MR, Pantarotto M, Torri V, Mangioni C, D'Incalci M: **Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer.** *Gynecol Oncol* 1997, **65**:130-137.
35. Aloyz R, Xu ZY, Bello V, Bergeron J, Han FY, Yan Y, Malapetsa A, Alaoui-Jamali MA, Duncan AM, Panasci L: **Regulation of cisplatin resistance and homologous recombination repair by the FTH1 subunit XPD.** *Cancer Res* 2002, **62**:5457-5462.
36. Sevin BU, Peng ZL, Perras JP, Ganjei P, Penalver M, Averette HE: **Application of an ATP-bioluminescence assay in human tumor chemosensitivity testing.** *Gynecol Oncol* 1988, **31**:191-204.
37. Smith HS, Zoli W, Volpi A, Hiller A, Lippman M, Swain S, Mayall B, Dollbaum C, Hackett AJ, Amadori D: **Preliminary correlations of clinical outcome with in vitro chemosensitivity of second passage human breast cancer cells.** *Cancer Res* 1990, **50**:2943-2948.
38. Nagai N, Minamikawa K, Mukai K, Hirata E, Komatsu M, Kobayashi H: **Predicting the chemosensitivity of ovarian and uterine cancers with the collagen gel droplet culture drug-sensitivity test.** *Anticancer Drugs* 2005, **16**:525-531.
39. Kim HA, Yom CK, Moon BI, Choe KJ, Sung SH, Han WS, Choi HY, Kim HK, Park HK, Choi SH, *et al*: **The use of an in vitro adenosine triphosphate-based chemotherapy response assay to predict chemotherapeutic response in breast cancer.** *Breast* 2008, **17**:19-26.
40. Cree IA, Kurbacher CM, Lamont A, Hindley AC, Love S: **A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer.** *Anticancer Drugs* 2007, **18**:1093-1101.

doi:10.1186/1479-5876-9-94

Cite this article as: Arienti *et al*: Peritoneal carcinomatosis from ovarian cancer: chemosensitivity test and tissue markers as predictors of response to chemotherapy. *Journal of Translational Medicine* 2011 **9**:94.